Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
NeoGenomics (NASDAQ: NEO) reported Q2 2026 total revenue of $202 million, up 11% year over year, with clinical services revenue up 14% to $187 million and NGS revenue up 26%. Gross profit rose 19% to $92 million with adjusted gross margin at 48%.
The company recorded GAAP net income of $2 million, including an $11 million gain on extinguishment of debt, versus a $45 million loss a year ago. Adjusted EBITDA increased 36% to $14 million. NeoGenomics generated $20 million of operating cash in Q2 and ended the quarter with $146 million in cash and investments. It completed a $316 million 0.75% convertible notes due 2032 offering, repurchased about $276 million of 2028 notes, executed capped calls, and repurchased $25 million of common stock. Updated 2026 guidance calls for revenue of $802–$806 million and adjusted EBITDA of $56–$58 million.
NeoGenomics (NASDAQ: NEO) announced a finalized civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving an investigation into consulting services tied to its Laboratory Collaboration Initiative. The Company, which self-disclosed the matter in November 2021, will pay $9,813,260 plus 4.250% annual interest from January 16, 2026 to the United States. NeoGenomics previously recorded an $11.2 million reserve for potential damages and liabilities. The settlement includes no admission of liability by NeoGenomics and no concession by the United States regarding its claims.
NeoGenomics (NASDAQ: NEO) launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for patients with prostate adenocarcinoma. The tissue-based test detects PTEN protein loss to help identify patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP (capivasertib).
The assay is performed by NeoGenomics pathologists across its national oncology laboratory network and is available as a standalone test or integrated into NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup. Prostate cancer affects over 300,000 men annually in the US, with about 8,750 mAPMN/S cases estimated to be PTEN-deficient each year.
NeoGenomics (NASDAQ: NEO) will report its second quarter 2026 financial results after the close of U.S. markets on Tuesday, July 28, 2026. Management will host a webcast and conference call at 4:30 p.m. ET for investors to review results and recent highlights.
NeoGenomics (NASDAQ: NEO) appointed Carolyn Starrett to its Board of Directors. Starrett has over 25 years of experience in commercial, product, and operations roles at data and technology companies, including Flatiron Health, and brings deep expertise in AI, real-world data, and oncology.
NeoGenomics (NASDAQ: NEO) priced a private offering of $275 million 0.75% convertible senior notes due 2032 to qualified institutional buyers, with an option for an extra $41.25 million. The notes carry a 0.75% coupon and mature on July 1, 2032.
The initial conversion price is about $14.16 per share, a 35% premium to the $10.49 last sale price, and NeoGenomics entered capped call transactions capped at $20.98 per share. Net proceeds are estimated at $266.15 million, mainly to fund capped calls, repurchase $276 million of 2028 notes, and buy back up to $25 million of common stock.
NeoGenomics (NASDAQ: NEO) began a private offering of $275 million convertible senior notes due 2032 to qualified institutional buyers under Rule 144A. Initial purchasers may buy up to an extra $41.25 million. NeoGenomics plans capped call transactions, partial refinancing of 0.25% notes due 2028, potential $25 million share repurchases, and use of remaining proceeds for general purposes.
NeoGenomics (NASDAQ:NEO) will present eight oncology research abstracts at the ASCO Annual Meeting 2026, May 29–June 2 in Chicago (booth #32130).
Highlights include MRD and ctDNA advances, colorectal cancer RaDaR ST data with MD Anderson, new biomarkers for targeted therapies, and an AML MRD flow assay.
NeoGenomics (NASDAQ:NEO) announced participation in two upcoming investor events. The company will attend the 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis with investor 1x1 meetings on Thursday, May 28, 2026.
NeoGenomics will also join the Jefferies Global Healthcare Conference 2026 in New York, hosting a fireside chat on Thursday, June 4, 2026 at 10:30 a.m. EDT, plus investor 1x1 meetings. A live webcast and replay will be available on its investor relations website.
NeoGenomics (NASDAQ: NEO) reported Q1 2026 results: consolidated revenue $187M (+11% YoY) and clinical revenue +14%, with NGS growth +26%. Adjusted EBITDA was $9M, net loss narrowed to $17M, and cash plus marketable securities totaled $146M. The company raised full‑year 2026 revenue guidance to $797–$803M. Key operational milestones include the commercial launch of RaDaR ST MRD, MolDX coverage for PanTracer LBx, and introduction of PanTracer Pro.